Legend Biotech (LEGN) Gross Profit (2022 - 2026)
Legend Biotech's (LEGN) quarterly Gross Profit came in at $129.7 million in Q1 2026, up 3.35% YoY from $125.5 million in Q1 2025, and down 18.46% on a QoQ basis from $159.1 million in Q3 2025.
Legend Biotech (LEGN) Gross Profit (2022 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 5 years of Gross Profit data on file, last reported at $129.7 million in Q1 2026.
- Quarterly Gross Profit rose 3.35% year-over-year to $129.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $574.5 million (up 16.89% YoY) and the FY2024 annual result came in at $410.9 million, up 191.59% from the prior year.
- Gross Profit slipped to $129.7 million in Q1 2026, from $159.1 million in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $79.4 billion in Q4 2023 to a low of $723000.0 in Q1 2023.
- A 5-year average of $5.8 billion and a median of $112.4 million in 2024 frame the typical range for Gross Profit.
- Annual changes were most pronounced in 2023 — Gross Profit soared 1701154.02% — and 2024, when it tumbled 99.85%.
- Tracing LEGN's Gross Profit over 5 years: stood at $4.7 million in 2022, then soared by 1701154.02% to $79.4 billion in 2023, then plunged by 99.85% to $117.1 million in 2024, then jumped by 35.84% to $159.1 million in 2025, then retreated by 18.46% to $129.7 million in 2026.
- The last three Gross Profit figures came in at $129.7 million (Q1 2026), $159.1 million (Q3 2025), and $160.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 251.50 Mn |
| Jun 30, 2026 | 251.50 Mn |
| Mar 31, 2026 | 129.70 Mn |
| Mar 31, 2026 | 129.70 Mn |
| Sep 30, 2025 | 159.07 Mn |
| Sep 30, 2025 | 159.07 Mn |
| Jun 30, 2025 | 160.19 Mn |
| Jun 30, 2025 | 160.19 Mn |
| Mar 31, 2025 | 125.50 Mn |
| Mar 31, 2025 | 125.50 Mn |
| Dec 31, 2024 | 117.10 Mn |
| Dec 31, 2024 | 117.10 Mn |
| Sep 30, 2024 | 107.70 Mn |
| Sep 30, 2024 | 107.70 Mn |
| Jun 30, 2024 | 141.17 Mn |
| Jun 30, 2024 | 141.17 Mn |
| Mar 31, 2024 | 44.89 Mn |
| Mar 31, 2024 | 44.89 Mn |
| Dec 31, 2023 | 79.43 Bn |
| Dec 31, 2023 | 79.43 Bn |